Retrophin Reports Third Quarter 2014 Financial Results
NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the quarter ended September 30, 2014.
“The successful re-launch of Thiola and accelerated uptake to end the third quarter was an important milestone for Retrophin, as our commercial products are demonstrating they will provide a strong foundation for sustained growth,” said Stephen Aselage, Chief Executive Officer of Retrophin. “We also began a period of important transition during the third quarter, which will better position the company to build on the commercial momentum of our marketed products and narrow our focus on the development of assets we believe will maximize future value for Retrophin, including sparsentan for FSGS and RE-024 for PKAN. In addition, we will continue to aggressively pursue business development opportunities that fit with Retrophin’s core competencies to support persistent returns.”
Help employers find you! Check out all the jobs and post your resume.
“The successful re-launch of Thiola and accelerated uptake to end the third quarter was an important milestone for Retrophin, as our commercial products are demonstrating they will provide a strong foundation for sustained growth,” said Stephen Aselage, Chief Executive Officer of Retrophin. “We also began a period of important transition during the third quarter, which will better position the company to build on the commercial momentum of our marketed products and narrow our focus on the development of assets we believe will maximize future value for Retrophin, including sparsentan for FSGS and RE-024 for PKAN. In addition, we will continue to aggressively pursue business development opportunities that fit with Retrophin’s core competencies to support persistent returns.”
Help employers find you! Check out all the jobs and post your resume.